Vilazodone, also known by its brand name Viibryd, became available as a generic in June 2022 after 11 years of market exclusivity. With the introduction of the Viibryd generic, the price of this multimodal antidepressant has significantly decreased, making it more accessible. However, the critical question remains: is vilazodone worth prescribing?
We’re taking a deep dive into Auvelity, a new antidepressant that combines Dextromethorphan and Bupropion. While Bupropion is well-established in the treatment of depression, Dextromethorphan is less familiar in psychiatric contexts.
Lurasidone (Latuda) has gone generic. Find out where this antipsychotic fits in bipolar disorder with updates from the 2023 International Bipolar Conference.
Chris Aiken, MD.
Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC.
Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Omega-3s are effective as augmentation of mood stabilizers in bipolar depression, and in some cases, they improve negative symptoms in early schizophrenia. The research is vast, but we narrow down when and how to use omega-3s in real-world practice.
Chris Aiken, MD.
Editor-in-Chief, The Carlat Psychiatry Report.
Lybalvi hopes to lower the risk of weight gain on olanzapine by combining it with an opioid blocker (samidorphan). But how does it compare to generic options like metformin and naltrexone?
Chris Aiken, MD.
Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC.
Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.
Chris Aiken, MD.
Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC.
In the last five years, more psychotropics have gained approval through the FDA’s expedited pathways than the slow and cautious routes we’ve grown used to. These “fast-track” and “breakthrough therapy” approvals allow drugs to enter the market on the basis of more efficient (ie, smaller) clinical trials.
Chris Aiken, MD.
Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC.
Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Most patients with bipolar disorder have cognitive complaints, but it’s a mistake to diagnose them all with ADHD, and a mistake to miss the genuine ADHD-bipolar comorbidity as well. Inside, a step-by-step guide to teasing apart the diagnoses.